Aquestive(US:AQST)2026-03-04 21:21Revenue Performance - Total revenues decreased by 23% or $13,016, from $57,561 in 2024 to $44,545 in 2025, primarily due to declines in license and royalty revenue, proprietary product revenue, and co-development fees [391]. - License and royalty revenue decreased by 77% or $11,826, from $15,345 in 2024 to $3,519 in 2025, primarily due to the one-time recognition of deferred revenues of $11,544 from terminated licensing agreements [393]. - Co-development and research fees decreased by 34% or $646, from $1,925 in 2024 to $1,279 in 2025, influenced by the timing of research and co-development performance obligations [394]. - Proprietary product revenue, net, reported a loss of $478 in 2025 compared to a revenue of $315 in 2024, indicating a significant decline [391]. - Proprietary product revenue, net decreased by $793, primarily due to the withdrawal of Libervant from the market [395]. Expense Overview - Total expenses increased, with selling, general and administrative expenses rising by 59%, or $29,669, compared to 2024 [400]. - Research and development expenses decreased by 15%, or $3,088, primarily due to lower clinical trial costs [398]. - Manufacturing and supply costs increased by 4%, or $683, due to changes in product mix and inventory write downs [397]. Cash Flow and Financing - Net cash used for operating activities increased by $16,673 in 2025 compared to 2024, totaling $(52,432) due to a net loss increase of $39,647 and higher trade receivables by $11,466 [416][417]. - Net cash provided by financing activities rose by $19,025 in 2025, totaling $102,617, primarily driven by net proceeds of $79,460 from the 2025 Underwritten Public Offering [419]. - The company expects to incur significant operating losses and negative cash flows for the foreseeable future, necessitating external financing to achieve its operating plan [425][424]. - The company completed a public offering of 21,250,000 shares at $4.00 per share, generating net proceeds of $79,900 after underwriting discounts [415]. Future Outlook and Strategic Plans - The company anticipates future manufacture and supply revenue to be based on volume demand for existing licensed products and new agreements for successful product development collaborations [369]. - The company plans to commercialize Anaphylm through its own sales force in the U.S. pending FDA approval, requiring significant funding for long-term support [426]. - The company anticipates continued investments in product development activities, particularly for Anaphylm and AQST-108, to support future growth [422]. Debt and Obligations - Interest expense includes costs on the outstanding balances of 13.5% Notes and amortization of issuance costs, with a tiered royalty obligation related to Anaphylm and Libervant sales [384]. - The company has a principal payment obligation of the 13.5% Notes starting in June 2026, which may require refinancing or amendments [420][423]. - The company has entered into various contractual agreements with long-term obligations, impacting its liquidity and operational flexibility [428]. - The company has entered into a Royalty Rights Agreement with Note Holders, granting a tiered royalty of 1.0% to 2.0% on annual worldwide net sales of Anaphylm and Libervant for a period of eight years [439]. - The value of the $45,000 13.5% Notes has been allocated between debt and royalty obligations based on their relative fair market values [439]. - The sale of future revenue related to KYNMOBI is treated as debt financing, amortized over the estimated life of the expected royalty stream [440]. - The liability related to the sale of future revenue is recorded at its proceeds, net of deferred costs, and is periodically assessed based on internal projections and external forecasts [440]. - Amortization of debt related to the sale of future revenue is reflected as interest expense in the Statements of Operations and Comprehensive Loss [440]. Shareholder Actions - The company sold 7,457,627 shares under the ATM facility in 2025, generating net proceeds of approximately $21,229 [407]. - A purchase and sale agreement was entered into for a payment of $75,000, contingent on FDA approval of Anaphylm [413]. - The company has committed to issue a warrant for up to 375,000 shares at an exercise price of $4.00 per share, expiring on March 3, 2029 [414].